CSIMarket Company Name, Ticker, Competitors, else..
 
Check cap Ltd   (CHEK)
Other Ticker:  
 
 
Price: $2.5000 $-0.09 -3.475%
Day's High: $2.91 Week Perf: 36.8 %
Day's Low: $ 2.46 30 Day Perf: 36.61 %
Volume (M): 213 52 Wk High: $ 5.90
Volume (M$): $ 532 52 Wk Avg: $1.45
Open: $2.70 52 Wk Low: $0.23



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 19
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 0

Check Cap Ltd


   Company Address: Check-Cap Building Isfiya 3009000
   Company Phone Number: 546706451   Stock Exchange / Ticker: NASDAQ CHEK
   CHEK is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vivos Therapeutics Inc

Deficit In spite of revenue growth at the company amid the fiscal first quarter of 2023

Investors in Vivos Therapeutics Inc received some mixed news during the first quarter of the 2023 earnings season. On the one hand, the company reported a net loss of $-0.07 per share, which was an improvement from the $-0.25 loss experienced a year ago. However, this also represented a decline from the previous quarter's $0.00 per share earnings.
Despite this mixed performance on the earnings front, the company experienced revenue growth of 5.845% when compared to the same quarter a year ago. During Q1 2023, Vivos Therapeutics Inc generated $3.86 million in revenue, up from $3.64 million a year ago. However, there was a sequential revenue decline of -2.354% from $3.95 million.
The Cooper Companies Inc

The Medical Equipment and Supplies company declared a single digit Top-line elevation, amid the fiscal second quarter of 2023

As a journalist, I have analyzed the financial results of The Cooper Companies Inc in the fiscal second quarter of 2023. The company's revenue managed to inch up by 5.736% to $877.40 million as compared to last year's $829.80 million. This suggests that the company has been able to generate more sales in the current period showcasing a positive trend. However, on the earnings per share front, things were not looking as good. The EPS dropped by -68.63% to $0.80 per share, from $2.55 in the previous quarter.
In comparison to the preceding period, revenue increased by 2.202%, but the profits plummeted drastically, with the EPS decreasing by -52.94% from $1.70. The company's bottom line of $39.800 million fell -68.56% from $126.600 million in the corresponding period a year earlier.
Ra Medical Systems Inc

Ra Medical Systems Inc has failed to turn into profitability despite of epic Surge in revenue in the January to March 31 2023 period

Ra Medical Systems Inc Achieves Strong Revenue Elevations in Q1 2023, But Reports Increased Loss Per Share
Ra Medical Systems Inc, a California-based medical device company that specializes in vascular and dermatology therapy, announced very strong revenue elevations of 844.444% year on year in the fiscal first quarter of 2023. The company's revenue for Q1 2023 was $0.09 million, a significant increase from its revenue of $0.01 million for the same period in 2022. Although the revenue increase is exciting news for Ra Medical, the company also reported an increase in its loss per share.
The loss per share for Q1 2023 was $-24.65, an alarming rise from the preceding quarter's loss per share of $-0.25 and from its previous net income of $0.00 million. The increase in loss per share can be attributed primarily to the company's recent investments in research and development and sales and marketing. These investments were necessary to boost product development and promote commercialization of Ra Medical's products.
Delcath Systems Inc

Delcath Systems Inc announced the deficit has been cut back remarkably, over the January to March 31 2023 period

Investors, get ready to rejoice! Delcath Systems Inc has delivered some impressive results for the first quarter of 2023. The company reported a whopping 57.937% revenue growth to $0.60 million, which has effectively helped to bring down losses to $-0.77 per share. This is a significant improvement from the $-1.00 per share loss reported in the same quarter last year.
Despite a decline in revenue in Q4, it's worth noting that the company managed to improve its EPS from $-0.88 to $-0.77 per share in the most recent quarter. It's always a good indication when a company is able to cut losses and improve profitability.
Haemonetics Corporation

Breathtaking financial reporting period by at the Haemonetics Corporation during the February to April 01 2023 span

Investors in Haemonetics Corporation can expect solid growth and increased earnings based on the company's fiscal fourth quarter 2023 financial results. The medical equipment and supplies company reported an impressive 71.13% increase in income per share to $0.77 compared to the previous year, while revenues grew by 31.706% to $342.13 million.
The company's net earnings also saw a healthy increase of 69.37% to $39.348 million. Although operating margin fell to 13.54%, the net margin actually improved to 11.5%. Operating earnings, however, only improved by 29.97% to $46.336 million.





 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071